Pembrolizumab for treating high-risk early-stage triple-negative breast cancer

Published on 02 Jan 2024
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with chemotherapy as neoadjuvant treatment and then continued as adjuvant monotherapy after surgery, for treating high-risk, early-stage, triple-negative breast cancer. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company.

Clinical indications, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex.

Pembrolizumab for treating high-risk early-stage triple-negative breast cancer (Published 2 Jan 2024) [PDF, 312 KB]

PES Pembrolizumab for treating high-risk early-stage triple-negative breast cancer (Published 2 Jan 2024) [PDF, 128 KB]